HYFT

MindWalk Holdings Corp. Common Stock

1.55 USD
-0.04
2.52%
At close Updated Sep 17, 4:00 PM EDT
Pre-market
After hours
1.56
+0.01
0.65%
1 day
-2.52%
5 days
-18.42%
1 month
-42.59%
3 months
63.8%
6 months
261.31%
Year to date
244.44%
1 year
167.7%
5 years
-90.3%
10 years
-90.3%
 

About: MindWalk Holdings Corp is an AI-driven biotherapeutic research, technology and scientifically robust life science company focused on the discovery and development of next-generation biologics. The Company combines scientific expertise with proprietary technologies such as its LENSai platform to accelerate drug discovery and improve decision-making across complex biological systems. It has several subsidiaries in North America and Europe, supporting global partners in advancing novel therapeutics, diagnostics, and translational research.

Employees: 102

0
Funds holding %
of 7,463 funds
Analysts bullish %

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

1,863% more call options, than puts

Call options by funds: $157K | Put options by funds: $8K

186% more capital invested

Capital invested by funds: $1.48M [Q1] → $4.23M (+$2.75M) [Q2]

33% more repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 6

5.28% more ownership

Funds ownership: 8.59% [Q1] → 13.88% (+5.28%) [Q2]

0% more funds holding

Funds holding: 24 [Q1] → 24 (+0) [Q2]

0% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 4

Financial journalist opinion

Based on 3 articles about HYFT published over the past 30 days

Neutral
Seeking Alpha
2 days ago
MindWalk Holdings Corp. (HYFT) Q1 2026 Earnings Call Transcript
MindWalk Holdings Corp. (NASDAQ:HYFT ) Q1 2026 Earnings Call September 15, 2025 10:30 AM EDT Company Participants Jennifer Bath - CEO, President & Non-Independent Director Joseph Scheffler - Interim Chief Financial Officer Conference Call Participants Swayampakula Ramakanth - H.C. Wainwright & Co, LLC, Research Division Presentation Operator Good morning, ladies and gentlemen, and thank you for joining us today for MindWalk's First Quarter Fiscal 2026 Earnings Call.
MindWalk Holdings Corp. (HYFT) Q1 2026 Earnings Call Transcript
Negative
Zacks Investment Research
2 days ago
MindWalk Holdings Corp. (HYFT) Reports Q1 Loss, Misses Revenue Estimates
MindWalk Holdings Corp. (HYFT) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.04. This compares to a loss of $0.11 per share a year ago.
MindWalk Holdings Corp. (HYFT) Reports Q1 Loss, Misses Revenue Estimates
Neutral
Business Wire
2 days ago
MindWalk Holdings Corp.™ (formerly ImmunoPrecise Antibodies™) Reports Record $7.6 Million Quarterly Revenue, 45% Growth, Margin Expansion, Narrowed Losses, and Strengthened Balance Sheet
AUSTIN, Texas--(BUSINESS WIRE)---- $HYFT #AI--MindWalk Holdings Corp.™ (“MindWalk™”, “Company”, “we” or “us”) (NASDAQ: HYFT), a Bio-Native AI company operating at the intersection of TechBio and next-generation drug discovery, today announced financial results for its first fiscal quarter of 2026, ended July 31, 2025. All numbers are expressed in Canadian dollars unless otherwise noted. First Quarter Highlights: Record revenue of $7.6 million, up 45% year-over-year; continued operations revenue of $3.2 milli.
MindWalk Holdings Corp.™ (formerly ImmunoPrecise Antibodies™) Reports Record $7.6 Million Quarterly Revenue, 45% Growth, Margin Expansion, Narrowed Losses, and Strengthened Balance Sheet
Charts implemented using Lightweight Charts™